HTH is an investment and advisory firm investing in health-focused innovators since 2016. They work closely with pharma companies to fund life science ventures, provide corporate innovation capabilities, and open stakeholder networks. Their science-first approach involves deep due diligence, including data, models, and clinical expert interviews, typically completed within 1-2 months.